US20260125779A1
ALLOYS FOR IMPLANTS
Publication
Application
Classifications
IPC Classifications
CPC Classifications
Applicants
Washington State University
Inventors
Amit Bandyopadhyay, Susmita Bose, Sushant R. Ciliveri, Indranath Mitra, William S. Dernell, Jose D. Avila
Abstract
A biocompatible alloy that includes titanium, copper, and at least one metallic element selected from: tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, and cobalt.
Figures
Description
[0001]This application claims the benefit of U.S. Provisional Appl. No. 63/705,984, filed Oct. 10, 2024, which is incorporated herein by reference in its entirety.
ACKNOWLEDGMENT OF GOVERNMENT SUPPORT
[0002]This invention was made with government support under grant numbers R01 AR067306 and R01 AR078241 awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND
[0003]Early-stage osseointegration is one of the most desirable qualities of metallic implants because it ensures faster healing and long-term implant stability, primarily depending on the implant's biocompatibility. Compromised biocompatibility due to bacterial growth on the implant has been shown to result in adverse events like septic loosening and prosthetic joint infection (PJI), which ultimately requires revision surgeries to mitigate such clinical challenges.
[0004]Growth in the incidence of revision surgeries due to PJI is projected to be 176% and 170% for THA and TKA by 2030, supporting prior literature suggesting a losing battle against this postoperative outcome. A recent World Health Organization report states that around 700,000 deaths occur yearly due to antimicrobial resistance (AMR). If no clinical remedies are found, as many as 10 million deaths per year are predicted by 2050 due to infection, higher than 8.2 million deaths per year due to cancer and will become a significant economic burden worldwide. In addition, the mortality rate for PJI is 87.3%, which is greater than those for colorectal and lung cancer and comparable to those for breast cancer (89%), which makes PJI a compelling and critical clinical challenge that needs immediate attention. Available therapy is based on a two-pronged approach of 1) extensive local debridement and implant replacement via revision surgery and 2) antibiotic treatments at the local surgery site or through systemic administration. However, those approaches are not always sustainable, leading to recurring infections even after revision surgery.
[0005]The interdependence of high infection rate (postoperative spine infection 0-18% and knee/hip arthroplasty 1-2%, revision surgeries (8-15% for arthroplasty), and out-of-pocket costs associated with such procedures (up to $93,000 in 2009) further complicate the problem. The most common infections originate from either Staphylococcus aureus (S. aureus˜66%) or Pseudomonas aeruginosa (P. aeruginosa˜15%, causing a recurrent infection rate for S. aureus following revision surgeries as high as 75% while only 56% are cured at 1-year post-op. In addition, infection of diverse types of implants such as hip, knee, and spine need highly heterogeneous modes of treatment, which can make healthcare complicated and expensive. This heterogeneity heavily biases material evaluation such as in vivo failure analyses, biological response, and implant success as a function of material properties. Therefore, implants should be self-sufficient to prevent prosthetic joint infections for better material evaluation and to mitigate the complexities of revision surgeries. Multifunctional materials such as Ti—Cu alloys can ensure implant success, access to healthcare use-costs, and increase value-of-product. So far, most studies have evaluated Ti implants alloyed with ≥5% Cu for bacterial resistance fabricated via powder metallurgy. However, the general perspective on such high amounts of copper addition in implant materials is linked to scientific concerns. Moreover, these studies do not account for any cytotoxicity from higher amounts of copper or evaluate ways of comprehensively improving the osseointegration ability of the implants.
[0006]Accordingly, a need exists for new methods and compositions for fortifying implants, in particular, titanium implants, to inherently protect the implant against bacterial infection while enhancing biocompatibility. In particular, alloying with, for example, metallic copper in a range from about 0.01 to about 30 wt %, based on the total weight of the alloy, will make the implant compositions disclosed herein bacteria-resistant long-term, leading to enhanced early-stage osseointegration and aids in resisting bacterial invasion and enhances osseointegration for faster healing and bone regeneration.
SUMMARY
- [0008]titanium, copper, and
- [0009]at least one metallic element selected from: tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, and cobalt.
[0010]Also disclosed herein is a biocompatible alloy comprising (i) titanium, (ii) copper and (iii) tantalum, niobium, or a mixture thereof.
[0011]Further disclosed herein is a biocompatible alloy comprising (i) titanium, (ii) copper, and (iii) magnesium oxide, silicon dioxide, or a mixture thereof.
[0012]The foregoing will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
[0046]
[0047]
DETAILED DESCRIPTION
[0048]In the description of the invention herein, it is understood that a word appearing in the singular encompasses its plural counterpart, and a word appearing in the plural encompasses its singular counterpart, unless implicitly or explicitly understood or stated otherwise. Furthermore, it is understood that for any given component or embodiment described herein, any of the possible candidates or alternatives listed for that component may generally be used individually or in combination with one another, unless implicitly or explicitly understood or stated otherwise. Moreover, it is to be appreciated that the figures, as shown herein, are not necessarily drawn to scale, wherein some of the elements may be drawn merely for clarity of the invention. Also, reference numerals may be repeated among the various figures to show corresponding or analogous elements. Additionally, it will be understood that any list of such candidates or alternatives is merely illustrative, not limiting, unless implicitly or explicitly understood or stated otherwise. In addition, unless otherwise indicated, numbers expressing quantities of ingredients, constituents, reaction conditions and so forth used in the specification and claims are to be understood as being modified by the term “about.”
[0049]Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the subject matter presented herein. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the subject matter presented herein are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical values, however, inherently contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0050]“Ti6Al4V” designates a titanium alloy with 6 wt. % Al and 4 wt. % V, based on the total weight of the alloy.
[0051]“Ti3Al2V” designates a titanium alloy with 3 wt. % Al and 2 wt. % V, based on the total weight of the alloy.
[0052]Disclosed herein are biological implant materials, particularly bone implant materials. In one aspect, the bone implant materials are additively manufactured compositions for load-bearing implants.
[0053]An aspect of the disclosure herein demonstrates that alloys, such as, but not limited to, Ti—Ta—Cu, provided inherent bacterial resistance suitable for load-bearing applications. Instead of using Ti6Al4V alloy, vanadium and aluminum contents were configured to design a Ti3Al2V alloy for metallic implant applications. Ta (e.g., 10 wt %) and Cu (e.g., 3 wt %) were added to the Ti3Al2V alloy to enhance biocompatibility and impart inherent bacterial resistance. Additively manufactured implants were thus utilized for resistance against Pseudomonas aeruginosa and Staphylococcus aureus strains of bacteria up to 72 h. The Cu addition to Ti3Al2V showed a surprising and unexpectedly improved antibacterial efficacy, i.e., 80% higher than CpTi (Commercially Pure Titanium) and Ti6Al4V. Resultant mechanical properties for Ti3Al2V-10Ta-3Cu demonstrated excellent fatigue resistance, good shear strengths, and better tribological characteristics than Ti6Al4V. In vivo studies using a rat distal femur model showed improved early-stage osseointegration for alloys with the, for example 10% Ta addition compared to CpTi and Ti6Al4V. The results show that a beneficial Ti3Al2V-10Ta-3Cu alloy synergistically improves in vivo biocompatibility and induces the inherent ability toward microbial resistance for the next generation of load-bearing metallic implants.
[0054]In certain embodiments, the alloy includes (i) titanium, (ii) copper, and (iii) tantalum and/or niobium. The tantalum and/or niobium improves biocompatibility, and the copper provides antibacterial resistance. In certain embodiments, the alloy also includes aluminum and vanadium. In certain embodiments, the alloy also includes zinc. Particular alloys include Ti—Ta—Cu; Ti—Ta—Cu—Al—V; Ti—Nb—Cu; Ti—Nb—Cu—Al—V; Ti—Ta—Nb—Cu; Ti—Ta—Nb—Cu—Zn; and Ti—Ta—Cu—Zn.
[0055]In certain embodiments, the copper is present in the alloy in an amount of about 0.01 wt % to about 30 wt %, more particularly about 0.01 wt % to about 15 wt %. In certain embodiments, the tantalum is present in the alloy in an amount of about 0.01 wt % to about 50 wt %. In certain embodiments, the niobium is present in the alloy in an amount of about 0.01 wt % to about 50 wt %. In certain embodiments, the aluminum is present in the alloy in an amount of about 0.01 wt % to about 10 wt %. In certain embodiments, the vanadium is present in the alloy in an amount of about 0.01 wt % to about 10 wt %. In certain embodiments, the zincs present in the alloy in an amount of about 0.01 wt % to about 10 wt %. In certain embodiments, titanium constitutes the remaining amount of the alloy.
[0056]In certain embodiments the alloy is manufactured using processes such as forging or casting, or is manufactured additively using powder sintering, or powder, wire, or sheet metal melting.
[0057]In certain embodiments, the tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, or cobalt is present in an un-melted form.
[0058]In certain embodiments, the tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, or cobalt is fully melted and alloyed with the titanium and copper.
[0059]In certain embodiments, the tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, or cobalt is present homogeneously throughout the bulk of the implant part alloy.
[0060]In certain embodiments, the tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, or cobalt is distributed locally in a specific area(s) of the implant part alloy.
- [0062]1. A titanium-based biocompatible metal alloy, comprising:
- [0063]an amount of titanium, aluminum and vanadium;
- [0064]wherein the amount of aluminum in the biocompatible metal alloy is in a range from about 1% to about 4.5% of the titanium amount, and wherein the vanadium amount varies from about 0.5% to about 3% of the titanium amount.
- [0065]2. The titanium-based biocompatible metal alloy of paragraph 1, wherein the biocompatible metal alloy is configured as a medical implant shaped for a subject body part.
- [0066]3. The titanium-based biocompatible metal alloy of paragraph 1, wherein the biocompatible metal alloy is configured as an industrial component.
- [0067]4. The titanium-based biocompatible metal alloy of paragraph 1, wherein the biocompatible metal alloy is processed via laser-based metal deposition in a controlled oxygen environment and coated on a desired metallic implant shaped for a subject body part.
- [0068]5. The titanium-based biocompatible metal alloy of paragraph 1, wherein the composition is processed via electron beam-based or plasma-based or electrical arc melting-based metal deposition in a controlled oxygen environment and coated on a desired metallic implant shaped for a subject body part.
- [0069]6. The titanium-based biocompatible metal alloy of paragraph 1, further comprising at least one metallic element selected from: tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, and cobalt.
- [0070]7. The titanium-based biocompatible metal alloy of paragraph 6, wherein the amount of at least one metallic element of the biocompatible alloy can be varied in a range from about 0.00 to about 50%.
- [0071]8. The titanium-based biocompatible metal alloy of paragraph 1, wherein the biocompatible metal alloy is further alloyed from at least one oxide selected from: magnesium oxide, silicon oxide, calcium oxide, strontium oxide, zinc oxide, tungsten oxide, lithium oxide, potassium oxide, sodium oxide, chromium oxide, molybdenum oxide, tin oxide, manganese oxide, iron oxide, and cobalt oxide.
- [0072]9. The titanium-based biocompatible metal alloy of paragraph 8, wherein the amount of at least one oxides of the biocompatible alloy can be varied in a range from about 0.00 to about 50%.
- [0073]10. The titanium-based biocompatible metal alloy of paragraph 1, wherein the biocompatible metal alloy includes copper and zinc.
- [0074]11. The titanium-based biocompatible metal alloy of paragraph 10, wherein the amount of copper is in a range from about 0.01 to about 30%.
- [0075]12. The titanium-based biocompatible metal alloy of paragraph 10, wherein the amount of zinc is in a range from about 0.01 to about 30%.
[0076]Turning specifically to the drawings,
Materials and Methods
Design and Fabrication: Selective Laser Melting (SLM)
[0077]CpTi and Ti6Al4V compositions were printed on a laser powder bed fusion (LPBF) system. A third composition was prepared and printed by mixing CpTi and Ti6Al4V powders in a 1:1 weight ratio, i.e., Ti3Al2V, since the amounts of Al and V were reduced by 50% each to 3 and 2 wt. %, respectively. Individual dense and porous (20 and 40% volume fraction porosity) cylindrical structures were designed for compression and shear strength measurements at the porous-dense interface. Alloy compositions Ti3Al2V-2Cu, Ti3Al2V-3Cu, Ti3Al2V-10Ta, and Ti3Al2V-3Cu-10Ta with 40% volume fraction porosity were built using LPBF for in vitro bacterial resistance studies and in vivo biological response studies. All structures were fabricated on a selective laser melting (SLM)-based PBF system (3D Systems ProX® DMP 200, Rock Hill, SC) with a 300 W fiber laser and wavelength 2=1070 nm. The system has a powder supply chamber and a melting stage. Spherical metal powders were used. CpTi powders were procured from GKN Hoeganaes (Cinnaminson, NJ, USA) and Ti6Al4V from AP&C (GE Additive, Cincinnati, Ohio, USA). Metal powders were sieved to obtain a particle size of <63 μm. These metal powders were added to the supply side. A CpTi build plate of ˜2.5 cm thickness was used and placed on the melting stage. The build chamber was enclosed and purged with argon gas with O2<500 ppm.
[0078]Additive manufacturing of Ti6Al4V and CpTi is widely used. The optimized laser power and scan speed parameters are 180 W and 1600 mm/s, respectively, for successful fabrication using a powder bed fusion (PBF) process, which was used for compositions CpTi, Ti6Al4V, Ti3Al2V, and Ti3Al2V-3Cu. With the addition of alloying elements, the part quality and print resolution varied depending on intrinsic material properties like heat diffusivity and laser absorption. Ta and Cu demonstrate contrasting laser-material interactions. Ta shows excellent laser absorption but has a very high melting point of 3017° C., indicating higher energy input for successful PBF. However, Cu is a poor laser absorber, reflecting 98% of the laser wavelengths in 1000-1100 nm range. Cu also demonstrates more than two times the viscosity and 100 times heat diffusivity in the molten state compared to Ti, dictating the higher energy required for the laser-PBF operation. An in-depth study on the powder bed fusion printing optimization for these alloys resulted in a laser power of 196 W and a scanning speed of 1440 mm/s to be the optimal printing parameters used to fabricate these compositions.
[0079]A layer thickness of 30 μm was used for each layer. The hexagonal laser scan strategy was used for dense and strip laser scan strategy for printing porous structures. All compositions were printed with the same print parameters (denoted as ‘as-printed’ structures hereafter). Post printing, structures were cut from the build plate and ground on 120 grit SiC papers to make the opposite surfaces parallel, followed by multiple sonication treatments in deionized (DI) water and ethanol, then compressed air spraying to remove all loose powders inside the pores. Bulk volume porosities were calculated by taking the measured volume of the structures to the theoretical volume of their respective dense composition. More information on design and porosity evaluation is presented in the supplemental file. Rectangular cross-section samples were manufactured for wear studies. Some of those samples were fabricated on a directed energy deposition (DED)-based AM system (FormALLOY, CA) and described briefly in the supplemental file.
Phase Analysis, Microhardness, and Microstructure
[0080]Phase detection was done using x-ray diffraction. Vickers microhardness tests were performed on the surface in the x-y plane of the build direction. Microstructure was observed by cutting longitudinally along the build direction. The sections were mounted in a phenolic resin followed by grinding on 80-1200 grit size SiC grinding papers and polishing using 0.05-1 μm of suspended alumina in deionized water (DI). The Vickers microhardness test was conducted on a Phase II Plus Micro Vickers Hardness tester (Upper Saddle River, NJ, USA) using a load of 200 gms and a dwell time of 15 s. A total of n=15 microhardness measurements were conducted for each composition. Surfaces were etched in Kroll's reagent for 45 s, and microstructures were observed under a Scanning Electron Microscope (SEM, Apreo, Thermo Scientific, MA, USA).
Mechanical Strength Evaluation: Compression, Shear, and Fatigue
[0081]As per ASTM E9-19, dense and porous cylindrical structures for all compositions with 7 mm diameter and ˜15 mm height were subjected to compression testing on Instron servo-hydraulic machine (600DXS, Grove City, Pennsylvania). At least 3 replicates were tested for each composition and porosity, respectively. A crosshead displacement rate of 1.3 mm/min was used across the compositions. The corresponding load-displacement data was recorded. Elastic modulus was calculated from the linear slope region from the stress-strain curve. Compressive yield strength was evaluated using the 0.2% strain offset method. Shear strength was evaluated at the porous-dense interface using a single-shear test device developed in our lab per the procedure described in reference. Structures with 3.1 mm diameter and ˜12 mm height were used. The nature of the shear test carried out is tensile rather than torsional. The porous-dense interface was placed at the interface of the shear plates and pulled in tension in opposite directions with a crosshead displacement rate of 0.3 mm/min on an Instron servo-hydraulic testing machine (600DXS, Grove City, Pennsylvania). An external 1360 kg load cell and an extensometer were used to precisely measure the load and displacement of the shear plates, respectively. Structures were sheared till fracture, and the corresponding load and displacement data were recorded. At least three replicates were tested for each composition and porosity, respectively. The shear modulus was evaluated as the slope of the linear region in the shear stress-strain curve. Maximum shear strength was evaluated as the highest shear strength endured by the structure before failure. Fractured surfaces at the porous-dense interface were observed under a Scanning Electron Microscope (SEM, Apreo, Thermo Scientific, MA, USA). No etching was done on fracture surfaces for microstructural imaging. The fatigue tests were performed on an ADMET eXpert 9300-Rotating Beam Fatigue system (Norwood, MA). The Rotating Beam tester applies a force via a bending moment to induce surface stress on a sample. Each surface experiences tensile and compressive stresses as the sample rotates until failure. The digital controller displays the number of cycles for the sample to fail.
Wear and Open Circuit Potential (OCP) Tests
[0082]In vitro tribological testing was carried out using a ball-on-flat set up on ground-polished DED printed CpTi, Ti6Al4V, Ti3Al2V, Ti3Al2V-3Cu, Ti3Al2V-10Ta and Ti3Al2V-10Ta-3Cu samples following ASTM G133-05 [17]. The tests were done using a Biotribometer (Ducom, India) in Dulbecco's Modified Eagle's medium (DMEM) (Sigma-Aldrich) with a 5 N applied load, 3 mm diameter zirconia (ZrO2) wear ball, translation speed of 72 m/h, and a 10 mm amplitude for a total sliding distance of 1000 m. Compound wear (CW) and coefficient of friction (COF) were recorded; compound wear for the tested samples was attained using the built-in linear variable differential transducer (LVDT) to measure the z-axis displacement of the tribological loading arm throughout testing. The measurement considers both wear on the counter wear ball and the tested sample, hence the compound wear. A 2-electrode corrosion-cell configuration acquired the open circuit potential (OCP) with a modular line Metrohm Autolab potentiostat/galvanostat (Riverview, FL, USA). The fabricated structures were used as the working electrode (WE), and the reference electrode (RE) was a saturated Ag/AgCl/KCl. The structures were immersed in DMEM and allowed to stabilize for a minimum of 2-3 h before starting the tribological wear test. The tracks on the samples and scars on the ZrO2 wear balls were imaged under a Scanning Electron Microscope (Quanta 200F, Thermo Fisher, Waltham, MA) and optical microscope, respectively.
In Vivo Study
[0083]Both dense and porous (40% volume fraction porosity) CpTi, Ti6Al4V, Ti3Al2V, Ti3Al2V-3Cu, and Ti3Al2V-10Ta-3Cu compositions were used for the in vivo biological response study. In vivo studies were designed with a 2-phase parallel evaluation. First, CpTi and Ti6Al4V were considered controls to evaluate the biological response of Ti3Al2V compositions. This phase was designed to assess whether Ti3Al2V had similar or better osseointegration than the already established CpTi without compromising the mechanical tissue-material fixation that Ti6Al4V offers. The second phase was a post-Ti3Al2V assessment to evaluate toxicity, enhancement in biological response, and osseointegration of Ti3Al2V-3Cu and Ti3Al2V-10Ta-3Cu over Ti3Al2V.
Surgery and Implantation Procedure
[0084]Male Sprague-Dawley rats with average weights between 300-350 gms were used for the in vivo study. The rats were acclimatized in separate cages in a temperature and humidity-controlled room for at least a week before the surgeries. The animals were administered buprenorphine (0.03 mg/kg) 30 minutes before anesthesia as a pain-reducing medication. The animals were anesthetized with a prescribed dose of IsoFlo® (isoflurane, USP, Abbott Laboratories, North Chicago, IL, USA) coupled with oxygen (Oxygen USP, A-L Compressed Gases Inc., Spokane, WA, USA) and periodically monitored by respiration rate during the surgery. Once anesthetized, the animals were shaved around the implantation area and cleaned thrice with alternating chlorhexidine and isopropyl alcohol scrubs. As a numbing agent, 0.3 ml of Lidocaine HCL (without epinephrine), 0.5% was administered subcutaneously on each leg near the incision area.
[0085]An incision was made on the lateral side above the distal femoral condyle, and a unicortical defect of 2.5 mm diameter was made on the lateral epicondyle using the gradually increasing diameter of drill bits. The defect site was rinsed with saline to prevent thermal necrosis and remove residual bone fragments, and the implant was placed in the defect. The fascia over the incision, followed by the skin, was then sutured using undyed braided coated MONOCRYL-polyglactin 910 (Ethicon Inc., Somerville, NJ, USA) outer skin was stapled using sterile surgical staples. An anti-inflammatory analgesic, meloxicam (0.2 mg/kg), and lactated ringer's solution-(LRS, 3 ml) for rehydration were administered post-surgery subcutaneously for the first 2-3 days, and the animals were monitored until they regained consciousness. Postoperative care was carried out for 3 days, with buprenorphine administration every 12 h and meloxicam every 24 h. After 6 weeks, the rats were euthanized by carbon dioxide overdose, followed by cervical dislocation as a secondary measure. The harvested metal-bone explants were fixed in 10% neutral buffered formalin for at least 72 h for tissue infiltration. The Institutional Animal Care and Use Committee (IACUC) of Washington State University (Pullman, WA) approved protocol was followed to perform the experimental and surgical procedure.
Histological Analysis
[0086]After fixing the explants in 10% neutral buffered formalin for 72 hours, serial dehydration was carried out in ethanol and embedded in polymethyl methacrylate (PMMA).
[0087]They were then sliced into thin sections along the longitudinal direction of the metal implantation and the surrounding bone using a Exakt™ saw, ground, and mounted on glass slides. Sanderson's Rapid Bone Staining (SRBS) and Hematoxylin and eosin (H&E) staining were carried out on separate glass slides for each composition for histological analysis. These stained bone sections were then observed under a Keyence digital microscope (Model VHX-7000, Itasca, IL), exploiting the microscope's multi-lighting and 3D-depth composition features to observe osteoid and trabecular bone formation at the bone-material interface.
Histomorphometry Analysis
[0088]The stained sections were imaged under a Keyence digital microscope (Model VHX-7000, Itasca, IL), and histomorphometry analysis was carried out using the microscope's multi-lighting and 3D-depth composition features, which allowed for accurate spherical rendering and detailed imaging of the histological features to the slide thickness. SRBS-stained slides were observed for osteoid and trabecular bone. H&E-stained sections were analyzed for any visible markers of the inflammatory response. Quantitative osseointegration at the bone-implant interface was inspected based on modified scoring criteria per, as shown in Table 1.
| TABLE 1 |
|---|
| Modified scoring for quantitative osseointegration at the bone-implant |
| interface following criteria per ISO 10993: 6 (2016) Annex E.2 |
| Score |
| Parameter | 0 | 1 | 2 | 3 | 4 |
| Trabecular | Absent | Minimal, | Mild, | Moderate, | Marked, |
| apposition | 1-25% | 26-50% | 51-75% | 76-100% | |
| Fibrocar- | Absent | Minimal, | Mild, | Moderate, | Marked, |
| tilage | 1-25% | 26-50% | 51-75% | 76-100% | |
| presence | |||||
| Osteoid at | No | osteoid | Mostly | A mix of | Mostly |
| interface | bone or | woven | woven and | lamellar | |
| osteogenic | bone | lamellar | bone | ||
| islands | bone | ||||
| fibrosis | absent | narrow | moderately | Thick | extensive |
| band | thick band | band | band | ||
| tissue | absent | minimal | mild | moderate | marked |
| ingrowth | |||||
| into the | |||||
| device | |||||
The modifications in the scoring criteria were decided based on parameters relevant to the scope of this research. The final scoring parameters were trabecular apposition, osteoid at the interface, fibrocartilage presence, inflammation (from H&E-stained sections), fibrosis, and tissue ingrowth into the implant. Out of these six parameters, the first three were quantified as the average area fraction of each parameter calculated using Trainable Weka Segmentation in ImageJ over 7 different sections under a high-power field (×1000) around the BIC region. Individual sections were further divided into 4 segments for the Random Forest Algorithm. The other four parameters were qualitatively evaluated from low-power field images of the tissue sections (See
In Vitro Bacterial Study
[0089]Bacterial culture was carried out for CpTi, Ti6Al4V, Ti3Al2V, Ti3Al2V-2Cu, and Ti3Al2V-3Cu using two relevant bacterial strains: Pseudomonas aeruginosa gram-negative bacteria for 36 h and Staphylococcus aureus gram-positive bacteria for 24 and 48 h Both strains of bacteria are relatively common in post-surgical orthopedic infections. Freeze-dried P. aeruginosa (Carolina Biological, NC) and S. aureus were rehydrated using rehydration media. Subsequently, dilutions in nutrient broth were made for 0.5 McFarland standard optical density measurement, the correct dilution of 106 CFU/ml. Disc samples were sterilized and studied in triplicate for agar plate colony count and duplicates for SEM characterization. Samples were placed in separate wells in 24 well-plate, and 106 CFU/ml of both bacterial colonies were seeded on the autoclaved polished surface augmented with 2 ml of nutrient broth per well. After respective time points, bacterial cells were scraped from the surface of the 3 out of 5 samples using cell scrapers, mixed in 2 ml 0.1M phosphate buffer saline (PBS), and serially diluted to approximately contain colonies between 30 and 300. 1 μl of the respective solutions were streaked on a cetrimide agar plate (Pseudosel agar, Fisher Scientific, NH) for P. aeruginosa and tryptic soy agar plates for S. aureus. Bacterial colonies on agar plates were counted after 24 hrs of incubation, and the antibacterial efficacy was evaluated as a function of bacterial colonies on individual material compositions as:
Where N is the calculated number of bacterial colonies observed, C is the average colony count on a plate, d=dilution factor, and 1=volume of bacterial suspension on the sample. To study the bacterial cell morphology, SEM samples were preserved in 1% glutaraldehyde and 1% paraformaldehyde in 0.1M phosphate buffer overnight, followed by dehydration, gold coating, and imaging was carried out on a Scanning Electron Microscope (SEM, Apreo, Thermo Scientific, MA, USA).
Results
[0090]The impact of the chemistry and structural design of 3D-printed Ti3Al2V alloys were evaluated for their mechanical and biological performance compared to CpTi and Ti6Al4V. Bulk porosity for as-printed dense and porous structures was evaluated separately using the same structures used for compression testing vis-à-vis Ti6Al4V and Ti3Al2V. For Ti6Al4V, the % bulk porosities were measured to be 3.7, 14.8, and 35.8%, denoted as Ti6Al4V-D, Ti6Al4V-P20, and Ti6Al4V-P40, respectively. Porosities for Ti3Al2V were 3.8, 19.2, and 42.9% and were denoted as Ti3Al2V-D, Ti3Al2V-P20, and Ti3Al2V-P40, respectively. The 3.6 and 3.8% porosities for Ti6Al4V-D and Ti3Al2V-D are residual. Although optimized processing parameters were used for all compositions, minor variations in porosities were observed due to a change in chemistry and related variations in laser absorptivity during processing.
Phase Analysis, Hardness, and Microstructure
[0091]
Mechanical Strength Characterization: Compression, Shear, and Fatigue
[0092]Metallic implants at load-bearing sites are constantly under multi-axial loading in vivo. It becomes essential to understand the mechanical behavior of such implants under different loading conditions to minimize the possibility of implant failures. Dense and porous samples for all compositions were subjected to compression loading, while dense-porous interface samples for Ti6Al4V and Ti3Al2V were subjected to shear loading, and only dense samples were subjected to fatigue loading. AM-processed Ti6Al4V was used as a positive control.
Shear Behavior
[0093]The weakest point lies in the porous-dense interface material design for porous coatings on the bulk implant. For Ti3Al2V to be a more versatile material, it is essential to evaluate the shear characteristics at this porous-dense interface to prevent coating failures in such coating applications [28]. SEM micrographs at the porous-dense failure interface,
Compressive Behavior
[0094]It is desired for an implant material to demonstrate an elastic modulus closer to that of the natural bone (˜5-30 GPa), with high yield strength. This reduction in elastic modulus is achieved by introducing controlled porosity in metallic implants. Elastic modulus and compressive yield strength values for dense and porous Ti6Al4V and Ti3Al2V against their evaluated porosities are plotted in
[0095]As opposed to the high compressive yield strength of Ti6Al4V˜1100 MPa, CpTi shows a yield strength as low as 432 MPa. This enhanced strength in Ti6Al4V is due to the addition of Al and V solute atoms inducing the formation of a high-strength-low modulus β-Ti phase in Ti6Al4V. The variation in compressive yield strength can be attributed to the composition and porosity. An 18% reduction in strength from Ti6Al4V-D (1181 MPa) to Ti3Al2V-D (965 MPa) was seen due to reduced Al and V amounts. From Ti6Al4V-P20 (922 MPa) to Ti3Al2V-P20 (719 MPa), a 22% reduction in compressive yield strength, with 4.4% higher measured porosity for Ti3Al2V-P20 than Ti6Al4V-P20 is observed. Similarly, Ti6Al4V-P40 (557 MPa) to Ti3Al2VP40 (382 MPa), with 7.1% higher porosity for Ti3Al2V-P40, reduced compressive yield strength by 31%. At the same time, the strength observed for Ti3Al2V-P40 (382 MPa, 42.9% porosity) is comparable to that of dense CpTi (˜350 MPa). For Ti3Al2V-10Ta-3Cu, the compressive yield strength increased to 1255±51 MPa. This enhancement in strength is due to the formation of Ti2Cu intermetallic formation in Ti3Al2V-10Ta-3Cu alloy and the solid solution strengthening effect due to Cu. Raw stress vs. strain plots for each porosity and composition are reported in (see
Fatigue Behavior
[0096]AM-processed dense fatigue samples of Ti6Al4V, Ti3Al2V, and Ti3Al2V-10Ta-3Cu at a 90° build angle were tested using an ADMET eXpert 9300-Rotating Beam Fatigue testing system. The 90° build angle is tested under fatigue loading as that is the weakest build direction due to being parallel to the loading direction. The fatigue specimens were turned to the final shape to minimize AM-generated surface roughness at the gauge length. Samples were then heat treated at 400° C. for 1 h and cooled slowly in the furnace to reduce residual stresses. After removal from the furnace, the sample is polished using emery cloth ranging from 400-600 grits until no defects are visible on the surface. Samples were tested to determine at what stress amplitude samples can survive at least 10 million cycles without failure. Ti6Al4V and Ti3Al2V samples survived 10 million cycles at 21% of their respective compressive yield strength. Anisotropy is an important factor in additively manufactured structures. Ti3Al2V structures at 0° build angle demonstrated almost two times higher fatigue endurance limit than Ti3Al2V at 90°. With a further increase in stress amplitude, samples failed at lower cycles. For the Ti3Al2V-10Ta-3Cu samples, no failure up to 10 million cycles was accomplished at 19% of the compressive yield strength. Our initial fatigue test results indicate that lowering Al and V in Ti and adding Ta and Cu do not degrade the excellent fatigue response of these alloys.
Tribological Study
[0097]Tribological testing and characterization are essential to any material for physiological load-bearing sites. Proper interpretation of the physical wear phenomena must be evaluated from the compound wear (CW) curve, coefficient of friction (COF), and worn surface imaging of the tested sample and the counter wear material; this is needed to determine the wear-induced degradation and material deformation thoroughly. Additionally, an investigation into the electrochemical passive nature of the material during tribological testing should be done. Such testing requires a data logging unit, known as a potentiostat, a working electrode (WE), a reference electrode (RE), and an electrically conductive media or an electrolyte. The results of such tribo-corrosive testing allow for quantification and further understanding of the material's chemical behavior or evolution during tribological testing; chemical changes usually occur within the passivation, de-passivation, and re-passivation domains. In the presence of physiological or simulated body fluid, such as electrolytes, the testing can be in vitro. The bio-tribo-corrosive results for these alloys are displayed in (see
Wear Behavior
[0098]Electron micrographs of the wear track surface and optical images of the counter wear ball were attained and are displayed in
Open Circuit Potentials (OCPs)
[0099]The acquisition of the OCP before and during tribological testing results in the curves displayed in
Histological Analysis-Bone-Implant Interface
[0100]In vivo rat model with CpTi as the positive and Ti6Al4V as the negative control was studied with dense and porous implants,
[0101]
| TABLE 2 |
|---|
| Statistical Tukey-Kramer pairwise comparison between all six |
| in vivo compositions for area fraction of mineralized bone |
| Mineralized Bone | |||
| Pairwise-Tukey Comparison | Difference in means | ||
| 1 | μTi6Al4V-μCpTi | Not Significant |
| 2 | μTi3Al2V-μCpTi | Not Significant |
| 3 | μTi3Al2V-μTi6Al4V | Significant |
| 4 | μTi3Al2V-3Cu-μCpTi | Not Significant |
| 5 | μTi3Al2V-3Cu-μTi6μAl4V | Not Significant |
| 6 | μTi3Al2V-3Cu-μTi3Al2V | Significant |
| 7 | μTi3Al2V-10Ta-μCpTi | Significant |
| 8 | μTi3Al2V-10Ta-μTi6Al4V | Significant |
| 9 | μTi3Al2V-10Ta-μTi3Al2V | Not Significant |
| 10 | μTi3Al2V-10Ta-μTi3Al2V-3Cu | Significant |
| 11 | μTi3Al2V-10Ta-3Cu-μCpTi | Not Significant |
| 12 | μTi3Al2V-10Ta-3Cu-μTi6Al4V | Significant |
| 13 | μTi3Al2V-10Ta-3Cu-μTi3Al2V | Not Significant |
| 14 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-3Cu | Significant |
| 15 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-10Ta | Not Significant |
| TABLE 3 |
|---|
| Statistical Tukey-Kramer pairwise comparison between all six |
| in vivo compositions for area fraction of osteoid tissue. |
| Pairwise-Tukey Comparison | Osteoid | Difference in means | ||
| 1 | μTi6Al4V-μCpTi | Not Significant |
| 2 | μTi3Al2V-μCpTi | Significant |
| 3 | μTi3Al2V-μTi6Al4V | Significant |
| 4 | μTi3Al2V-3Cu-μCpTi | Significant |
| 5 | μTi3Al2V-3Cu-μTi6Al4V | Significant |
| 6 | μTi3Al2V-3Cu-μTi3Al2V | Not Significant |
| 7 | μTi3Al2V-10Ta-μCpTi | Significant |
| 8 | μTi3Al2V-10Ta-μTi6Al4V | Significant |
| 9 | μTi3Al2V-10Ta-μTi3Al2V | Not Significant |
| 10 | μTi3Al2V-10Ta-μTi3Al2V-3Cu | Not Significant |
| 11 | μTi3Al2V-10Ta-3Cu-μCpTi | Significant |
| 12 | μTi3Al2V-10Ta-3Cu-μTi6Al4V | Significant |
| 13 | μTi3Al2V-10Ta-3Cu-μTi3Al2V | Not Significant |
| 14 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-3Cu | Not Significant |
| 15 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-10Ta | Not Significant |
| TABLE 4 |
|---|
| Statistical Tukey-Kramer pairwise comparison between all six |
| in vivo compositions for area fraction of fibrocartilage. |
| Fibrocartilage | |||
| Pairwise-Tukey Comparison | Difference in means | ||
| 1 | μTi3Al2V-μTi6Al4V | Not Significant |
| 2 | μTi3Al2V-3Cu-μTi6Al4V | Not Significant |
| 3 | μTi3Al2V-3Cu-μTi3Al2V | Not Significant |
| 4 | μTi3Al2V-10Ta-μTi6Al4V | Not Significant |
| 5 | μTi3Al2V-10Ta-μTi3Al2V | Not Significant |
| 6 | μTi3Al2V-10Ta-μTi3Al2V-3Cu | Significant |
| 7 | μTi3Al2V-10Ta-3Cu-μTi6Al4V | Not Significant |
| 8 | μTi3Al2V-10Ta-3Cu-μTi3Al2V | Not Significant |
| 9 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-3Cu | Not Significant |
| 10 | μTi3Al2V-10Ta-3Cu-μTi3Al2V-10Ta | Not Significant |
[0102]The H&E staining for the bone-implant sections was primarily evaluated for in vivo inflammatory response towards Ti3Al2V, Ti3Al2V-3Cu, and Ti3Al2V-10Ta-3Cu chemical makeup as an implant material. None of the three material compositions show inflammatory markers or responses, including necrosis and neoplasia. Even though H&E histology micrographs are represented in varying shades of pink/purple, visible demarcations are present for all compositions, which aids in determining their relative biological responses. The SRBS histology micrographs for dense and porous implants show qualitative evidence of new bone or osteoid formation, osteoblast recruitment, and bone maturation or trabecular bone formation in the region of interest across all compositions except for Ti6Al4V. However, detailed analysis suggests gaps at the bone-implant contact (BIC) surface with multiple focal fibrocartilaginous areas at BIC for CpTi. Markedly, there was no significant bone ingrowth into the pores in CpTi. Some areas show interwoven lamellar bone into the fibrocartilage in Ti3Al2V. The lighter blue stain indicates the onset of fibrocartilage with more flattened and organized elongated cell rows. In comparison, Ti6Al4V shows almost 90% of the interface area covered with fibrous tissue (dark blue), including pore infiltration with isolated areas of osteoid presence. Some areas show old/matured cortical bone segments from surgical procedures. Fibrocartilage presence at a distance from the implant shows inferior osseointegration affinity towards the implant material. On the other hand, Ti3Al2V shows no gaps at the BIC with very well-apposed osteoid tissue (reddish orange) and continuing osteoblast recruitment. Bone tissue infiltration takes precedence over fibrocartilage into the porous channels of the bulk implant.
[0103]Ti3Al2V-3Cu alloys show similar characteristics of bone remodeling to CpTi implants with osseous tissue at the BIC and interwoven lamellar bone into the implant surface. The fibrocartilage that runs through the porous channel has focally embedded new bone tissue. Ti3Al2V-10Ta shows enhanced bone ingrowth into the implant's pores and osteoid lining fronts, suggesting continued bone remodeling. However, the fibrocartilaginous presence in Ti3Al2V-3Cu alloys is shown to be restored to the bony formation and new osteoid tissue inside the pores of the implant in Ti3Al2V-10Ta-3Cu compositions with the addition of 10% Ta.
[0104]Quantitative histomorphometry (Table 5 shown below in combination with
| TABLE 5 |
|---|
| Showing scored parameters for bone regeneration around |
| BIC based on scoring criteria mentioned earlier. |
| Ti3Al2V- | |||||||
| CpTi | Ti6Al4V | Ti3Al2V | Ti3Al2V-3Cu | Ti3Al2V-10Ta | 10Ta-3Cu | ||
| Trabecular | 1 | 1 | 2 | 1 | 2 | 2 |
| apposition | ||||||
| Fibrocartilage | 0 | 1 | 1 | 1 | 1 | 1 |
| presence | ||||||
| Osteoid at the | 1 | 1 | 3 | 2 | 4 | 3 |
| interface | ||||||
| Inflammation | 0 | 0 | 0 | 0 | 0 | 0 |
| Fibrosis | 0 | 2 | 0 | 1 | 0 | 0 |
| Tissue | 1 | 0 | 3 | 1 | 4 | 4 |
| ingrowth into | ||||||
| the device | ||||||
[0105]First, the numbers show a uniform fibrocartilage presence across all the compositions, whether visibly at the BIC extended from the lateral edge of the implant exposed to multiple different tissues apart from the osseous phenotype. Such fibrocartilage response is expected at an early timeframe, like 6 weeks, which then develops into woven bone. However, there is only a significant difference in fibrocartilage presence in Ti3Al2V-3Cu (11.8±4) and Ti3Al2V-10Ta (5.2±2) due to much higher trabecular bone presence for Ti3Al2V-10Ta (46±3) compared to other compositions.
[0106]Comparing the box plots for mineralized bone and osteoid presence at the BIC (see
Infection Prevention and Bacterial Resistance
[0107]Both CpTi and Ti6Al4V do not possess inherent antibacterial resistance [32], [33]; therefore, we do not expect any antibacterial properties in Ti3Al2V by extension. However, since post-surgical implant site infection is a common denominator in orthopedic material (see
[0108]This data was beneficial for establishing Ti3Al2V—Cu alloys as a material for implant applications. A secondary bacterial culture with a different strain of bacteria S. aureus (gram-positive), for 24 and 48 h on all compositions was performed to confirm the antibacterial efficacy of the alloys herein. Bacterial cells were counted in triplicate from SEM micrographs/unit area based on magnification instead of the agar plate method. % Living bacteria for Ti3Al2V-2Cu and 3Cu compared to CpTi at 24 h of culture were 23 and 14%, respectively. However, at 48 h there was a slight but insignificant increase in the bacterial count for both compositions. A similar result as with the previous bacteria was observed for Ti3Al2V, the % bacterial viability was significantly lower than CpTi and 46 and 36% after 24 and 48 h of culture, respectively. According to the SEM micrographs shown in (see
[0109]MgO and Cu were incorporated into CpTi matrix to enhance its osteogenic potential and imbue inherent bactericidal capabilities.
[0110]This Ti—MgO—Cu material chemistry is expected to enhance early-stage osseointegration due to osteogenic MgO and prevent polymicrobial infection incidence at the implant site, ensuring the implant's long-term stability and preventing the need for revision procedures due to their aseptic loosening. This study aims to fabricate CpTi, CpTi+1 wt. % MgO (CpTi—MgO), and CpTi+1 wt. % MgO+3 wt. % Cu (CpTi—MgO—Cu) compositions using metal-AM. These compositions were characterized for microstructure and microhardness evaluations. In vivo rat studies were conducted to evaluate the biological performance of these compositions. Structures utilized for the in vivo studies were ˜40 vol. % porous with an approximate pore size of 600-700 μm since pore sizes in this range are optimum for enhanced tissue integration and osseointegration. Additionally, in vitro bacterial culture was studied using the commonly occurring Staphylococcus aureus bacterial strain to evaluate the antibacterial efficacy of CpTi-MgO—Cu. We hypothesize that the CpTi—MgO—Cu composition will demonstrate better osseointegration performance than CpTi in vivo with no cytotoxicity due to the presence of Cu, as schematically shown in
Materials and Methods
Processing of Samples Using Metal Additive Manufacturing
[0111]CpTi, CpTi—MgO, and CpTi—MgO—Cu compositions were processed using metal additive manufacturing. A metal matrix composition of CpTi—MgO was prepared by premixing CpTi powders (GKN Hoeganaes, Cinnaminson, NJ) with 1 wt. % of MgO (Inframat® Advanced Materials™, Manchester, CT) powders. Similarly, CpTi—MgO—Cu composition was prepared by premixing CpTi powders with 1 and 3 wt. % s of MgO and Cu (GKN Hoeganaes, Cinnaminson, NJ) powders, respectively. All metal and ceramic powders used for fabrication were sieved to obtain a powder particle size of <63 μm. All metal and ceramic powers used were spherical. The fabrication used two AM processes: directed energy deposition (DED) and selective laser melting (SLM). Samples for in vitro study were printed on a 5-axis DED-based AM system (FormAlloy, Spring Valley, CA). Although coarser powder particles (45-150 μm) are preferred for DED-based AM systems, we have optimized the print parameters to accommodate finer particle sizes of <63 μm for the printing operation. The printing operation was conducted in an argon-purged environment with O2<20 ppm in the print chamber. A cold rolled CpTi substrate was used as a build plate. Discs of 8 mm diameter and 4 mm height were printed on the DED system. The printing parameters used for the compositions are presented in Table 1. Samples used for in vivo study were printed on an SLM-based powder bed fusion system (3D Systems ProXR DMP 200, Rock Hill, SC) with a 300 W fiber laser and wavelength 2=1070 nm. Porous structures of 2.4 mm diameter and 4 mm height with ˜40 vol. % porosity were designed in 3DXpert CAD Software (3D Systems, Rock Hill, SC). Premixed powders were poured into the supply chamber and compacted using a companion plate. A thick CpTi plate of ˜2.5 thickness was used as the build platform and placed-secured on the melting stage. A roller system carried powders from the supply to the build stage, with 30 μm as the layer thickness. The laser power and scanning speed for all the compositions are reported in Table 1. 3D Systems provide printing parameters used for CpTi and CpTi—MgO as the standard Ti print parameters. Laser power has been increased by 10% and scan speed reduced by 10% to increase the print energy input for CpTi—MgO—Cu since Cu displays poor laser absorption and needs higher energy for additive operation. Porous cylinders post-printing were cut from the build plate and subjected to repeated sonication in de-ionized (DI) water and ethanol, followed by compressed air treatment to remove any loose powder particles inside the pores. The final step in residual powder removal involved acid etching in 1% H.F. in DI water. The samples were sonicated again in DI water and ethanol to remove any acid residues.
| TABLE 6 |
|---|
| Print-processing parameters used for DED and PBF operations of additively |
| manufactured CpTi, CpTi—MgO, and CpTi—MgO—Cu compositions. |
| DED (in vitro, microstructure, hardness) |
| Laser | Scan speed | |||||
| power (W) | (mm/min) | Shield gas | Carrier gas | Powder disc | Slice |
| Composition | Contour | Hatch | Contour | Hatch | (l/min) | (l/min) | speed (rpm) | (mm) |
| CpTi | 350 | 350 | 1500 | 1200 | 18 | 14 | 0.7 | 0.3 |
| CpTi—MgO | ||||||||
| CpTi—MgO—Cu | ||||||||
| PBF (in vivo ~40% porosity) |
| Laser | Scan | ||||
| power | speed | Slice | |||
| Composition | (W) | (mm/s) | (μm) | ||
| CpTi | 180 | 1600 | 30 | ||
| CpTi—MgO | |||||
| CpTi—MgO—Cu | 198 | 1440 | |||
Microhardness and Microstructure
[0112]DED printed discs were cut off the build plate and subjected to grinding on SiC grinding papers, 80-2000 grit size. This was followed by alumina suspension polishing, reducing the alumina powder particle size from 1-0.05 μm. Vickers microhardness test was conducted on a Phase II Plus Micro Vickers Hardness tester (Upper Saddle River, NJ, USA) using a load of 200 gms and a dwell time of 15 s. Hardness values on a polished surface perpendicular to the build direction were obtained. An n=5 measurement was taken for each point. For acquiring the microstructures, polished surfaces of the discs were etched in Kroll's reagent for 45 s and observed under a Scanning Electron Microscope (SEM, Apreo, Thermo Scientific, MA, USA).
In Vitro Bacterial Study—Staphylococcus aureus
[0113]Bacterial culture was carried out on CpTi and CpTi—MgO—Cu to evaluate the antibacterial resistance using Staphylococcus aureus gram-positive bacterial strain for 24, 48, and 72 h. Freeze-dried S. aureus (Carolina Biological, NC) was rehydrated using rehydration media. Tryptic soy broth was used as the nutrient medium. The rehydrated bacterium was subjected to nutrient broth dilutions to obtain 0.5 McFarland standard optical density measurement corresponding to 106 CFU/ml of bacteria. Polished disc samples were sterilized before culture, placed in 24 well plates, and studied in triplicate for agar plate colony count and duplicates for SEM characterization. 106 CFU/ml of bacterial colonies were seeded on the surface of the discs, with 2 ml of tryptic soy broth added as the nutrient medium in each well. After the respective time points, bacterial cells from triplicate samples for agar plate colony count were scraped using cell scrapers and mixed in 2 ml of 0.1 M PBS and serially diluted to approximately contain 10 to 100 colonies in 1 μl of the solution. 1 μl of this solution was streaked on a tryptic soy agar plate and incubated for 24 hrs. The duplicate samples used to observe the bacterial cell morphology were subjected to a fixative solution, dehydrated as described in Section 2.4, and observed under a Scanning Electron Microscope (Quanta 200F, Thermo Fisher, Waltham, USA). Images were taken at 300× for each composition, and the number of bacterial cells was counted on at least n=4 images for each composition. The antibacterial efficacy for agar plate count at 24 hrs was evaluated as a function of bacterial colonies counted on individual material compositions, as
Where N is the calculated number of bacterial colonies observed, C is the average colony count on a plate, d=dilution factor, and l=volume of bacterial suspension on the sample. Antibacterial efficacy from SEM images was evaluated for 24, 48, and 72 h time points and calculated for R, with N being the average number of bacterial cells from multiple SEM images.
In Vivo Study
[0114]CpTi, CpTi—MgO, and CpTi—MgO—Cu compositions were subjected to an in vivo rat study. CpTi is known to demonstrate excellent in vivo biological performance and is used as a control. Adding MgO to CpTi is expected to show better early-stage osseointegration performance than CpTi. PBF-fabricated porous implants with ˜40 vol. % porosity were used for the study.
Surgery and Implantation Procedure
[0115]Male Sprague-Dawley rats with average weights between 300-350 gms were used for the in vivo study. Post procurement, the animals were acclimatized in temperature and humidity-controlled rooms in separate cages for at least two weeks. Buprenorphine (0.3 mg/kg) for alleviating pain was subcutaneously administered to the animals 30 mins before anesthesia. A prescribed dose of IsoFlo® (isoflurane, USP, Abbott Laboratories, North Chicago, IL, USA) coupled with oxygen (Oxygen USP, A-L Compressed Gases Inc., Spokane, WA, USA) was used to anesthetize the animals. Once the animal's movements ceased under anesthesia, the implantation area around the femur and the knee was shaved thoroughly and cleaned thrice with chlorohexidine and isopropyl alcohol scrubs. 0.3 ml of Lidocaine HCL (without epinephrine), 0.5% as a localized numbing agent, was subcutaneously administered near the implantation area on each leg. The animal was transferred onto a sterile surgery table area. A 2-inch incision was made along the femur on the lateral side above the distal femoral condyle. A unicortical defect of 2.4 mm diameter was made on the lateral epicondyle using gradually increasing drill bits and rinsed with saline to prevent thermal necrosis and remove bone fragments. The implant was placed, the fascia was over the incision, and the skin was sutured with undyed braided coated MONOCRYL-polyglactin 910 (Ethicon Inc., Somerville, NJ, USA). The incision area was cleaned with saline scrubs and stapled. A similar procedure was carried out on the other leg of the animal. The animal was periodically monitored by respiration rate during the surgery procedure. Lactated ringers solution (LRS, 3 ml) for rehydration was subcutaneously administered to the animal post-surgery, followed by meloxicam (0.2 mg/kg) administration as an anti-inflammatory analgesic, and monitored until the animal regained consciousness. Postoperative care was carried out for 3 days, with buprenorphine administration every 12 hours and meloxicam every 24 hours. The animals were euthanized after 6 weeks of surgery by carbon dioxide overdose, followed by cervical dislocation as a secondary measure, and the femoral bone with the metal implant was harvested. The Institutional Animal Care and Use Committee (IACUC) of Washington State University (WSU-Pullman, WA) approved protocol was followed to perform the experimental and surgical procedure.
Histological and Histomorphometric Analysis
[0116]The bone-metal explants were fixed in 10% neutral buffered formalin for at least 72 hrs for tissue infiltration. Serial dehydration in ethanol followed by embedment in polymethyl methacrylate (PMMA). These embedded bone explants were cut on Ekakt™ saw into 200 μm thin sections, mounted on glass slides, and then ground to 20-50 μm thick sections using 1200 grit size sanding paper on Ekakt 400 micro grinder. The sections were then polished on the micro grinder using 4000 grit-size paper. Gomori trichrome, Hematoxylin & Eosin (H&E), and Sanderson's Rapid Bone Staining (SRBS) were the stains on separate bone sections for each composition. The stained bone sections were imaged on a Keyance digital microscope (Model VHX-7000, Itasca, IL). H&E-stained slides were imaged for any visible markers indicating an inflammatory response in areas around the implant. Gomori trichrome-stained slides were observed for muscle fibers and collagen presence at the bone-implant contact (BIC), and SRBS-stained slides for mineralized bone formation, osteoid presence at the BIC, and mineralization fronts.
[0117]Histomorphometric analysis was carried out using SRBS-stained slides for each composition. To restrict the region of interest (ROI) to 100-150 μm from the implant surface, images were captured at 1000× magnification around the bone-implant contact (BIC) region. Quantitative evaluation of mineralized bone formation at the BIC was carried out using Trainable Weka Segmentation in ImageJ with Random Forest Algorithm for individual images. At least 7 regions were analyzed to quantify mineralized bone formation at the BIC and presented in % area fraction.
Results
[0118]CpTi shows good biocompatibility and no cytotoxicity. Its lack of strength and fatigue resistance over Ti6Al4V makes it a popular coating material choice over bulk Ti6Al4V implants. However, it is bio-inert and possesses no antibacterial capabilities. The surface properties of the implant influence its biological performance in the physiological environment. This study aims to enhance the early-stage osseointegration of CpTi with MgO addition and induce inherent antibacterial capabilities by adding Cu. This CpTi—MgO—Cu material chemistry is expected to show superior biological performance in vivo compared to CpTi and can be a potential metallic coating material of choice on bulk metallic implants.
Microstructure and Hardness
[0119]SEM micrographs of the etched surface,
[0120]Vickers microhardness measurements conducted on the polished surface of the DED printed compositions,
Histological Analysis and Histomorphometry—Bone-Implant Interface
[0121]To assess the biological performance of the compositions in a physiological environment, an in vivo rat model was utilized. CpTi was considered the control with CpTi—MgO and CpTi—MgO—Cu as the treatment compositions.
[0122]The observations described above are further supported by the H&E-stained histology micrographs,
[0123]SRBS-stained histological micrographs, shown in
Infection Prevention
[0124]CpTi inherently does not possess antibacterial resistance. In order to address post-surgical infections, the addition of Cu was implemented in the CpTi—MgO composition. Cu is well-known for inhibiting bacterial growth through the on-contact killing of bacterial cells. Since Staphylococcus aureus is one of the most commonly occurring infections in vivo, the antibacterial efficacy of the CpTi—MgO—Cu material against this bacterial strain at 24, 48, and 72-h time points using CpTi as the negative control was evaluated,
[0125]The volume of orthopedic surgeries has been experiencing an exponential rise, with over 7 million orthopedic surgeries performed in the U.S. alone. According to a National Ambulatory Medical Care survey, 70% of patients visiting clinics for orthopedic surgery-related issues in 2015-2016 were over 45 years of age. Age plays a significant role in the quality of recovery, as the quality of bone and its healing ability significantly decreases with age. Elderly patients, who often suffer from immunocompromised bone health, experience prolonged recovery after surgery, compromising their overall health. Incidence of infections at the implant site requiring revision surgery, the impact on the patient's health is substantial, particularly for individuals with age-related degradation of bone health, leading to a further reduction in life expectancy. There is an unmet need in metallic implants for materials that can provide faster bone remodeling performance and infection prevention capabilities beyond what titanium currently offers. Current strategies include cemented implants with Ti6Al4V as the bulk material for strength with a surface coating of bioactive calcium phosphate (CaP) or hydroxyapatite (H.A.). Although cemented implants show superior in vivo performance towards early-stage osseointegration, one of the primary roadblocks includes delamination of the CaP coating due to poor metal-ceramic bonding. Instead, using porous titanium metallic coatings is a popular choice to abate the risk of coating failures. In order to induce osteogenic properties in these porous titanium coatings, MgO addition in CpTi can potentially solve the coating failure issue.
Osteogenesis Due to MgO Addition
[0126]Mg plays an essential role in promoting bone calcification and remodeling. Mg deficiency in the bone has been linked with degenerative bone diseases such as osteoporosis. Mg regulates intracellular calcium ion concentration, pH, transporters, enzymes, and protein synthesis. Biodegradable Mg implants for low-load bearing bone-graft applications have been studied extensively. Moreover, incorporating MgO in calcium phosphate has enhanced cellular proliferation in vitro and osteogenic performance in vivo. In this study, incorporating MgO in CpTi enhanced osteogenesis at the bone-implant interface. With just 1 wt. % MgO addition in CpTi, mineralized bone formation at the BIC increased four-fold compared to that in CpTi,
Antibacterial Performance Due to Cu Addition
[0127]The first recorded use of copper as a bactericidal date back 5000 years in Egyptian medical texts as a sterilizing agent for chest wounds. Having been used copper for medical purposes throughout the following generations, its antibacterial potential was realized in the 19th century. In 2011, copper was the first antimicrobial metallic material by the U.S. Environmental Protection Agency (EPA). Amid the current pandemic, in 2021, U.S. EPA announced and approved copper disinfecting products owing to the performance of copper and copper alloys against SARS-COV-2, i.e., the virus responsible for COVID-19. Realizing the potential of Cu as an antibacterial agent, extensive research has been conducted on incorporating Cu into Ti. Cu is a necessary trace element in the human body in a wide variety of tissues, but higher amounts of Cu can cause cytotoxicity leading to liver cirrhosis and neurologic abnormalities. A debate persists on the optimum amount of Cu in Ti. In this study, with 3 wt. % addition of Cu in CpTi, the H&E-stained bone sections show no signs of cytotoxicity. However, the mineralized bone formation in CpTi—MgO—Cu was observed to be lower than that in CpTi—MgO. Although 3 wt. % Cu did not cause cytotoxicity; there was a delayed early-stage osseointegration performance. CpTi—MgO—Cu still showed 3.5× mineralized bone formation at the interface than CpTi, showing superior osteogenic performance.
Early-stage osseointegration greatly affects the patient's recovery time. With CpTi—MgO—Cu used as a metallic coating on bulk Ti6Al4V alloy at load-bearing sites, coating failures in cemented implants can be avoided. At the same time, enhanced early-stage osseointegration can be achieved owing to the osteogenic properties of MgO, and inhibition of bacterial infections at the surgery site can prevent revision surgeries.
[0128]Early-stage osseointegration at the implant surface is critical in the post-surgery healing of elderly patients with degraded bone health. Ti's bio-inertness and non-antibacterial nature result in aseptic loosening and necessitate surgical intervention. Without adequate material intervention enhancing tissue integration and preventing polymicrobial infections, revision procedures further degrade the patient's health and potential patient morbidity. Ti6Al4V bulk implants coated with bioactive ceramics with osteogenic MgO and antibacterial Cu currently serve the purpose of coating failures due to weak metal-ceramic being a roadblock. Instead, we propose the addition of 1 wt. % MgO and 3 wt. % Cu in CpTi matrix as a coating on Ti6Al4V to prevent delamination failure owing to a strong Ti-on-Ti interface. In vivo studies showed superior osteogenic performance by CpTi—MgO and CpTi—MgO—Cu compositions. Histomorphometric evaluations reveal 4× enhanced mineralized bone formation in CpTi—MgO (49.5±11.5%) and 3.5× in CpTi—MgO—Cu (38.2±7.2%) in comparison to CpTi (12.1±9.2%) at the bone-implant interface. Additionally, no cytotoxicity was caused by 3 wt. % Cu addition. Antibacterial studies with commonly occurring Staphylococcus aureus bacterial stain showed up to 81% bactericidal effect by Cu in CpTi—MgO—Cu composition at the end of 72 hrs. A multifaceted metal-ceramic coating CpTi—MgO—Cu material makeup on bulk Ti6Al4V could serve as an ideal material for orthopedic implant applications with a reduction in implant failures and the need for revision surgeries due to delayed early-stage osseointegration and infection-related issues.
[0129]A multifaceted metal-ceramic system, CpTi—SiO2-3Cu, was developed with enhanced early-stage osseointegration and bactericidal capabilities due to SiO2 and Cu, respectively. The amount of SiO2 was restricted to 1 wt. % to reduce the brittleness of the metal-ceramic systems. Considering the possibility of Cu toxicity, only 3 wt. % Cu was added. The compositional design (CpTi+1 wt. % SiO2+3 wt. % Cu) coupled with the structural modification, i.e., porosities, has been implemented using AM. The compositions were tested for their biological performance and possible Cu cytotoxicity through in vivo rat studies. The antibacterial performance of CpTi—SiO2-3Cu was investigated via in vitro bacterial culture with Staphylococcus aureus bacterial strain, a commonly occurring bacterial infection in the human body. CpTi—SiO2-3Cu will demonstrate superior early-stage osseointegration to CpTi with inherent antibacterial capabilities. We anticipate that such composition can be used as a potential choice of monolithic material for low-load bearing implant applications and as a surface coating on Ti6Al4V for orthopedic devices (
Materials and Methods
Additive Manufacturing of CpTi—SiO 2 -3Cu
[0130]This study utilized CpTi, CpTi—SiO2, and CpTi—SiO2-3Cu compositions. To process the CpTi-SiO2 metal matrix composition, CpTi powders (GKN Hoeganaes, Cinnaminson, NJ) were mixed with 1 wt. % of SiO2 powder (Chemsavers Inc., Bluefield, VA). Similarly, the CpTi—SiO2-3Cu composition was prepared by premixing CpTi powders with 1 wt. % of SiO2 powders and 3 wt. % of Cu powders (GKN Hoeganaes, Cinnaminson, NJ). All metal and ceramic powders used in the additive manufacturing (AM) process were sieved to achieve a particle size<63 μm and possessed a spherical shape.
[0131]This study used directed energy deposition (DED) and selective laser melting (SLM) based AM processes to fabricate metal and metal-ceramic composite samples. Dense discs of ˜8 mm diameter and ˜4 mm height were printed on a 5-axis DED system (FormAlloy, Spring Valley, CA) for hardness, microstructure, and in vitro studies. Printing was conducted in an argon-purged environment within the print chamber, maintaining 02 levels below 20 ppm. A cold rolled CpTi substrate served as the build plate for the process. The DED system utilizes coaxially flown premixed powders from the laser head, converging on a point where the laser melts the powders on the build plate. The specific print parameters are provided in Table 1. Samples intended for in vivo study were printed on an SLM-based powder bed fusion (PBF) system, 3D Systems ProX® DMP 200 (3D Systems, Rock Hill, SC). This system is equipped with a 300 W fiber laser having a wavelength of 2=1070 nm. Porous structures with a diameter of 2.4 mm and a height of 4 mm, comprising ˜40 vol. % porosity, were designed using 3DXpert CAD Software (3D Systems in Rock Hill, SC). The premixed powders were placed in the supply chamber and compacted using a compaction plate. A thick CpTi plate with a thickness of approximately 2.5 cm was utilized as the build platform and securely positioned on the build stage. A roller system transported the powders from the supply to the build stage, with a layer thickness of 30 μm. The laser power and scanning speed for all the compositions are reported in Table 7. After printing, porous cylinders were cut from the build plate and subjected to repeated sonication in de-ionized (DI) water and ethanol, followed by compressed air treatment to remove loose powder particles from the pores. The final step involved acid etching in 1% HF in DI water to remove loosely attached powders. The samples were then sonicated again in DI water and ethanol to remove any acid residues.
| TABLE 7 |
|---|
| Additive manufacturing of CpTi, CpTi—SiO2, and CpTi—SiO2-3Cu |
| compositions via DED and PBF operations. |
| DED (in vitro, microstructure, hardness testing samples) |
| Laser | Scan speed | |||||
| power (W) | (mm/min) | Shield gas | Carrier gas | Powder disc | Slice |
| Composition | Contour | Hatch | Contour | Hatch | (l/min) | (l/min) | speed (rpm) | (mm) |
| CpTi | 350 | 350 | 1500 | 1200 | 18 | 14 | 0.7 | 0.3 |
| CpTi—SiO2 | ||||||||
| CpTi—SiO2-3Cu | ||||||||
| PBF (in vivo samples with 40% porosity) |
| Laser | Scan | ||||
| power | speed | Slice | |||
| Composition | (W) | (mm/s) | (μm) | ||
| CpTi | 180 | 1600 | 30 | ||
| CpTi—SiO2 | |||||
| CpTi—SiO2-3Cu | 198 | 1440 | |||
Phase Analysis, Microhardness, and Microstructure
[0132]DED-printed discs were cut from the build plate into individual discs using a water-jet system and subjected to grinding using SiC grinding papers with grit sizes ranging from 80 to 1200. Subsequently, alumina suspension polishing was done with a stepwise reduction of particle size of the alumina powder suspended in DI water from 1 to 0.05 μm. The polished discs were then analyzed for phase detection, microhardness, and microstructure. Phase analysis was done on a Siemens D5000 x-ray diffraction system (Siemens, Washington DC, USA) equipped with a θ-θ goniometer geometry using a Kα radiation of 15.4 nm wavelength. The intensity of the peaks within the 30°≤2θ≤80° range was observed. Microhardness testing was performed using a Phase II Plus Micro Vickers Hardness tester (Upper Saddle River, NJ, USA) with a 200 g load and a dwell time of 15 s. For microstructural analysis, the polished surfaces of the discs were etched for 45 s using Kroll's reagent and examined on a Keyance VHX-970FN optical microscope (Keyance Corporation of America, Itasca, IL).
In Vitro Bacterial Study-Staphylococcus aureus Bacterial culture was performed on CpTi (negative control) and CpTi—SiO2-3Cu samples to assess the antibacterial resistance against the gram-positive bacterial strain Staphylococcus aureus. The culture was conducted for 24, 48, and 72 h. Freeze-dried S. aureus (Carolina Biological, NC) was rehydrated using a rehydration media. The rehydrated bacteria were serial diluted in nutrient broth to achieve an optical density of 0.5 McFarland standard, corresponding to 1.5×108 CFU/ml of bacteria. Before the culture, the polished disc samples were sterilized and placed in 24-well plates. The experiments were conducted in triplicate for agar plate colony count and duplicates for SEM characterization. 106 CFU of bacterial colonies were seeded on the surface of the discs with 2 ml of tryptic soy broth added to each well as the nutrient medium. Agar plate characterization was employed for 24 h, and SEM for all three-time points. For agar plate characterization, bacterial cells from the triplicate samples for agar plate count were scraped using cell scrapers and mixed with 2 ml of 0.1 M PBS. The mixture was then serially diluted to yield a solution containing approximately 10 to 100 colonies in 10 μl of the PBS solution. 10 μl volume of this solution was streaked on a tryptic soy agar plate and incubated for 24 h. The antibacterial efficacy was evaluated by comparing the bacterial colonies counted on the different material compositions. The calculation of colony count (N) was determined using the formula;
where C represents the average colony count on a plate, d is the dilution factor, and l is the volume of bacterial suspension on the sample. The antibacterial resistance (R) was expressed as a percentage using the equation,
[0133]The duplicate samples for observing bacterial cell morphology were preserved in a fixative solution of 2% glutaraldehyde and 2% paraformaldehyde in 0.1 phosphate buffer overnight at 4° C. The samples were thrice rinsed in 0.1 M PBS and subjected to dehydration in 2% osmium tetraoxide (OsO4) for 2 h. The samples were then subjected to serial dehydration in ethanol and finally critical drying using hexadimethylsilazane (HMDS). These samples were examined under a scanning electron microscope (SEM) after gold coating on Apreo, Thermo Scientific, MA, USA. Bacterial efficiency at the end of each 24-48-72 h was calculated from bacterial colony counts from triplicate SEM images captured at 5000× magnification using equation (2).
In Vivo Study
[0134]CpTi, CpTi—SiO2, and CpTi—SiO2-3Cu compositions were subjected to an in vivo rat study. Adding SiO2 to CpTi is expected to show better early-stage osseointegration performance than CpTi. PBF-fabricated porous implants with ˜40 vol. % porosity were used for the study.
Surgery and Implantation Procedure
[0135]For the in vivo study, male Sprague-Dawley rats weighing 300-350 grams were used. Upon procurement, the rats were acclimatized in separate cages within temperature and humidity-controlled rooms for at least two weeks. 30 min before the surgery, the rats were subcutaneously administered Buprenorphine (0.3 mg/kg) to alleviate the pain. Anesthesia was induced using a prescribed dose of IsoFlo® (Isoflurane, USP, Abbott Laboratories, North Chicago, IL, USA) in combination with oxygen. Once the rats were fully anesthetized and immobile, the surgical area around the femur and knee was shaved and cleaned meticulously with alternate chlorhexidine and isopropyl alcohol scrubs. 0.3 ml of lidocaine HCL (without epinephrine), 0.5% was injected subcutaneously near the implantation area on each leg to provide localized numbing. The rats under anesthesia were then placed on a sterile surgical table. A 2-inch incision was made along the lateral side of the femur, above the distal femoral condyle. Using gradually increasing drill bits, a unicortical defect with a diameter of 2.4 mm was created on the lateral epicondyle. Saline was used to rinse the area during the drilling process to prevent thermal necrosis and remove bone fragments. The implant was inserted, and the fascia over the incision site, followed by the skin, was sutured using undyed braided coated MONOCRYL-polyglactin 910 sutures (Ethicon Inc., Somerville, NJ, USA). The incision area was cleaned with saline scrubs and stapled. The same procedure was performed on the other leg of each rat. Throughout the surgery, the rats' respiration rate was monitored periodically. After the surgery, the rats were administered subcutaneous injections of lactated ringers' solution (LRS, 3 ml) for rehydration, followed by meloxicam (0.2 mg/kg) as an anti-inflammatory analgesic. The rats were closely monitored until they regained consciousness. Postoperative care was provided for 3 days, including buprenorphine administration every 12 hours and meloxicam administration every 24 h. After 6 weeks, the rats were euthanized using carbon dioxide overdose, followed by cervical dislocation as a secondary measure. The femoral bone with the metal implant was then harvested. These bone-metal explants were fixed in 10% neutral buffered formalin for a minimum of 72 h to facilitate tissue infiltration. The experimental and surgical procedures followed the approved protocol of the Institutional Animal Care and Use Committee (IACUC) at Washington State University (Pullman, WA).
Histological and Histomorphometric Analysis
[0136]The bone-metal explants were immersed in 10% neutral buffered formalin for at least 72 hours to facilitate tissue infiltration. Subsequently, a series of dehydration steps in ethanol was performed, followed by embedding the specimens in polymethyl methacrylate (PMMA). These embedded bone explants were sliced into thin sections measuring 200 μm using an Ekakt™ saw. The sections were then mounted on glass slides and further reduced to 20-50 μm thickness using 1200 grit-size sanding paper on an Ekakt 400 micro grinder. Once the desired thickness was achieved, the sections were polished using 4000 grit-size paper on the micro grinder. To analyze the bone sections, Gomori trichrome, Hematoxylin & Eosin (H&E), and Sanderson's Rapid Bone Staining (SRBS) were applied as different staining techniques for each composition. The stained bone sections were observed using a Keyance digital microscope (Model VHX-7000, Itasca, IL). Visible markers indicating an inflammatory response in the vicinity of the implant were examined through imaging of slides stained with H&E. Muscle fibers and the presence of collagen at the bone-implant contact (BIC) were observed on Gomori trichrome-stained slides. Mineralized bone formation, the presence of osteoid at the bone-implant contact (BIC), and mineralization fronts were assessed on SRBS-stained slides. Histomorphometric analysis was conducted using SRBS-stained slides for each composition. To focus on the region of interest (ROI) within 100-150 μm from the implant surface, images were captured at 1000× magnification around the BIC area for the SRBS-stained slides. Quantitative evaluation of mineralized bone formation at the BIC was performed using Trainable Weka Segmentation in ImageJ with the Random Forest Algorithm applied to individual images. A minimum of 7 regions were analyzed to quantify the extent of mineralized bone formation at the BIC, which was presented as the percentage of area fraction.
Results
[0137]CpTi is used for surface coating on Ti6Al4V at load-bearing hip, knee, ankle, and spinal devices or as the sole implant material at low load-bearing sites, such as maxillofacial and dental implants. This study introduced enhanced biological functionalities in the CpTi matrix by SiO2 and Cu addition. Physical and mechanical characterizations have been carried out via microstructure, Vickers microhardness, and phase analysis. The biological performance of the CpTi—SiO2-3Cu chemical makeup has been evaluated by studying the bone-formation characteristics in vivo using a rat distal femur model. Antibacterial efficacy was measured via in vitro bacterial culture using the most commonly occurring bacterial infection strain, Staphylococcus aureus or S. aureus.
Physical and Mechanical Properties
[0138]SLM process involves a high cooling rate (˜104-106 K/s) that prevents long-range diffusion and thermodynamically stable phase formation, α(hcp) phase in the case of CpTi. Non-equilibrium martensitic phases are formed featuring metastable α′—Ti phases with acicular needle-like morphology,
Histological Analysis and Histomorphometry of Bone-Implant Interface
[0139]Assessing the efficacy of the material composition in vivo is essential for a comprehensive understanding of its biological performance. A successful biological fixation of an implant is governed by bone-implant contact (BIC), a critical indicator of osseointegration. CpTi, CpTi-SiO2, and CpTi—SiO2-3Cu were subjected to an in vivo rat distal femur model, with CpTi as the control. The bone sections post-explantation were subjected to various staining procedures such as Gomori Trichrome, Hematoxylin & Eosin (H&E), and Sanderson's Rapid Bone Staining (SRBS),
[0140]In contrast to H&E-stained histology, SRBS-stained micrographs (
Infection Prevention Capability
[0141]Bactericidal performance is one of the most essential sought-after properties in an implant material. With the widespread prevalence of postoperative bacterial infections at the implant site, an implant material with antibacterial capabilities will minimize the need for revision surgical procedures and implant replacement, ensuring implant longevity in vivo. Since CpTi does not possess inherent antibacterial capabilities, this study added bactericidal Cu to CpTi to incorporate antibacterial performance via on-contact bacterial killing exhibited by Cu. Bacterial viability for CpTi—SiO2-3Cu was tested against CpTi control with gram-positive S. aureus bacterial stain.
[0142]Ti is biocompatible yet bioinert. It does not aid in accelerated bone healing and attachment to host bone, an essential factor for patients with compromised bone health. In this study, SiO2 was added as an angiogenic agent for accelerated tissue engineering. Si4+ ions are present in trace amounts in the inorganic bone and are known to stimulate angiogenesis, i.e., help generate new blood vessels sprouting from existing ones (host bone). This angiogenic activity is essential in the regeneration and repair of bone and muscle on the implant surface since blood vessels supply essential nutrients and oxygen. The bone regeneration process starts with stimulating stem cells to enable angiogenesis, followed by osteogenic stimulation toward vascular bone formation. Si4+ ion incorporation in bioglass, crystalline ceramics, and composites such as calcium phosphate and hydroxyapatite have been found to promote osteogenesis and angiogenesis. The material makeup with ceramic matrix does not qualify for a long-term implant application due to its bioresorbable nature. The brittleness of the ceramic matrix is another concern with the chances of implant failure. However, SiO2 in CpTi matrix investigated in this study can be used as a potential long-term implant surface composition. From histology images for CpTi—SiO2, the tissue growth on the implant's outer surface can be seen to infiltrate the implant region, suggesting a higher affinity of tissue growth to the material composition. On the contrary, CpTi showed gaps between the mineralization front and the implant's outer surface, revealing slower osseointegration. Quantitative histomorphometry from SRBS-stained histology micrographs supports the qualitative results; with 4.5× higher mineralized bone formation at the bone-implant interface than in CpTi, CpTi—SiO2 exhibited enhanced osteogenic performance.
[0143]Curbing implant-related infections is another essential parameter contributing to the implant's long-term longevity and stability. Secondary infections at the implant site necessitate revision surgery procedures, further deteriorating the patient's health. Cu is a popular antibacterial agent alloyed with Ti. Cu is a necessary trace element in the body, but higher amounts of Cu are cytotoxic. With studies on varying amounts of Cu in Ti, a debate persists on the optimum amount of Cu in Ti without causing cytotoxicity. In this study, 3 wt. % Cu was added to the CpTi-matrix with 1 wt. % SiO2 for osteogenesis and angiogenesis. From the H&E histology micrographs,
[0144]CpTi—SiO2-3Cu composition showed no cytotoxicity in vivo with excellent antibacterial capabilities and superior osteogenic performance to CpTi. This composition displayed enhanced biological performance towards the two primary parameters responsible for implant longevity and stability: enhanced early-stage osseointegration and bactericidal performance. CpTi—SiO2-3Cu composition has the potential to replace CpTi as the material of choice for low load-bearing implant sites such as dental and cranial devices and coating on Ti6Al4V for high load-bearing implants such as hip and knee prosthesis.
[0145]The implant's in vivo longevity and stability is primarily governed by its early-stage attachment to the host bone. Aseptic loosening of implants, either due to improper bone attachment or infections, necessitates revision procedures that affect the patient's health. CpTi does not offer either enhanced early-stage osseointegration or antibacterial performance. Despite this, CpTi is still used as the preferred implant material for low load-bearing applications or as a porous coating on Ti6Al4V at load-bearing sites. To overcome the shortcomings of CpTi, we have explored a multifaceted CpTi chemical makeup: 1 wt. % angiogenic-osteogenic SiO2 and 3 wt. % Cu added to CpTi. These compositions were processed via additive manufacturing (AM) since it provides freedom of design; AM enables processing structures with designed porosities, promoting osseointegration at the implant's surface. In vivo studies revealed superior osseointegration performance by CpTi—SiO2 composition over CpTi. The qualitative comparison revealed gaps at the bone-implant interface for CpTi, whereas tissue infiltration into the implant's outer surface for CpTi—SiO2 suggests a higher affinity of tissue growth and maturation towards the CpTi—SiO2 chemical makeup. Quantitative histomorphometry revealed 4.5 times higher bone formation in CpTi—SiO2 than in CpTi. Although Cu is cytotoxic in large amounts, 3 wt. % of Cu in CpTi—SiO2-3Cu showed no inflammatory markers but slightly delayed osseointegration compared to CpTi—SiO2. CpTi—SiO2-3Cu displayed 3 times more bone formation than CpTi. In vitro bacterial studies with S. aureus revealed 85% antibacterial efficiency for CpTi—SiO2-3Cu to CpTi at the end of 72 h. With enhanced bone formation and maturation and excellent antibacterial capability displayed, CpTi—SiO2-3Cu with enhanced biological functionalities has the potential to replace CpTi, ensuring a reduction in revision surgery needs owing to poor implant attachment and bacterial infections.
[0146]In view of the many possible embodiments to which the principles of the disclosed compositions and methods may be applied, it should be recognized that the illustrated embodiments are only preferred examples and should not be taken as limiting the scope of the disclosed compositions and methods.
Claims
What is claimed is:
1. A biocompatible alloy comprising:
titanium, copper, and
at least one metallic element selected from: tantalum, niobium, zirconium, zinc, tungsten, lithium, potassium, strontium, sodium, calcium, chromium, molybdenum, tin, manganese, iron, and cobalt.
2. The biocompatible alloy of
3. The biocompatible alloy of
4. The biocompatible metal alloy of
5. The biocompatible alloy of
6. The biocompatible alloy of
7. A biocompatible alloy comprising (i) titanium, (ii) copper and (iii) tantalum, niobium, or a mixture thereof.
8. The biocompatible alloy of
9. The biocompatible alloy of
10. The biocompatible alloy of
11. The biocompatible alloy of
12. The biocompatible alloy of
13. The biocompatible alloy of
14. The biocompatible alloy of
15. The biocompatible alloy of
16. The biocompatible alloy of
17. The biocompatible alloy of
18. The biocompatible alloy of
19. The biocompatible metal alloy of
20. A biocompatible alloy comprising (i) titanium, (ii) copper, and (iii) magnesium oxide, silicon dioxide, or a mixture thereof.